f Varespladib: An Oral Treatment for Snakebite Envenoming

References

1. Snakebite envenoming 2024Available from: https://www.who.int/health-topics/snakebite#tab=tab_1
2. Snakebite envenoming–A strategy for prevention and control 2019 Available from: https://www.who.int/publications/i/item/9789241515641
3. KnudsenC. LaustsenA. Recent advances in next generation snakebite antivenoms.Trop. Med. Infect. Dis.2018324210.3390/tropicalmed3020042 30274438
   [Google Scholar]
4. LongbottomJ. ShearerF.M. DevineM. AlcobaG. ChappuisF. WeissD.J. RayS.E. RayN. WarrellD.A. Ruiz de CastañedaR. WilliamsD.J. HayS.I. PigottD.M. Vulnerability to snakebite envenoming: A global mapping of hotspots.Lancet20183921014867368410.1016/S0140‑6736(18)31224‑8 30017551
   [Google Scholar]
5. CasewellN.R. JacksonT.N. LaustsenA.H. SunagarK. Causes and consequences of snake venom variation.Trends Pharmacol. Sci.202041857058110.1016/j.tips.2020.05.006 32564899
   [Google Scholar]
6. GutiérrezJ.M. AlbulescuL.O. ClareR.H. CasewellN.R. Abd El-AzizT.M. EscalanteT. RucavadoA. The search for natural and synthetic inhibitors that would complement antivenoms as therapeutics for snakebite envenoming.Toxins202113745110.3390/toxins13070451 34209691
   [Google Scholar]
7. LewinM.R. CarterR.W. MatteoI.A. SamuelS.P. RaoS. FryB.G. BicklerP.E. Varespladib in the treatment of snakebite envenoming: Development history and preclinical evidence supporting advancement to clinical trials in patients bitten by venomous snakes.Toxins2022141178310.3390/toxins14110783 36422958
   [Google Scholar]
8. LewinM. SamuelS. MerkelJ. BicklerP. Appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase a2 and a possible pre-referral treatment for envenomation.Toxins20168924810.3390/toxins8090248
   [Google Scholar]
9. ParnhamM. J. Inflammation: mechanisms and therapeutics.Drug News Perspect.19969631639
   [Google Scholar]
10. NichollsS.J. KasteleinJ.J. SchwartzG.G. BashD. RosensonR.S. CavenderM.A. BrennanD.M. KoenigW. JukemaJ.W. NambiV. WrightR.S. MenonV. LincoffA.M. NissenS.E. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.JAMA2014311325226210.1001/jama.2013.282836 24247616
    [Google Scholar]
11. CarterR.W. GerardoC.J. SamuelS.P. KumarS. KotehalS.D. MukherjeeP.P. ShiraziF.M. AkpunonuP.D. BammigattiC. BhallaA. ManikathN. Platts-MillsT.F. LewinM.R. The BRAVO clinical study protocol: Oral varespladib for inhibition of secretory phospholipase a2 in the treatment of snakebite envenoming.Toxins20221512210.3390/toxins15010022 36668842
    [Google Scholar]
12. FernándezM.L. QuartinoP.Y. Arce-BejaranoR. FernándezJ. CamachoL.F. GutiérrezJ.M. KuemmelD. FidelioG. LomonteB. Intravascular hemolysis induced by phospholipases A 2 from the venom of the Eastern coral snake, Micrurus fulvius: Functional profiles of hemolytic and non-hemolytic isoforms.Toxicol. Lett.2018286394710.1016/j.toxlet.2017.11.037 29197624
    [Google Scholar]
13. TasoulisT. IsbisterG. A review and database of snake venom proteomes.Toxins20179929010.3390/toxins9090290 28927001
    [Google Scholar]
14. WangY. ZhangJ. ZhangD. XiaoH. XiongS. HuangC. Exploration of the inhibitory potential of varespladib for snakebite envenomation.Molecules201823239110.3390/molecules23020391 29439513
    [Google Scholar]
15. GutiérrezJ.M. LewinM.R. WilliamsD.J. LomonteB. Varespladib (LY315920) and methyl varespladib (ly333013) abrogate or delay lethality induced by presynaptically acting neurotoxic snake venoms.Toxins202012213110.3390/toxins12020131
    [Google Scholar]
16. Broad-spectrum rapid antidote: Varespladib oral for snakebite (BRAVO)2024Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04996264